Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel combined with pulsatile erlotinib in metastatic NSCLC
2007-001555-19Phase 2Terminated
- Sponsor
- HeCOG
- Start
- Dec 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of erlotinib and docetaxel in non-small cell lung cancer (NSCLC) (2 arms), sponsored by HeCOG. Primary endpoint: Progression-free survival. Started Dec 2007; status: terminated.
02
Drugs
erlotinibdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2007-001555-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001555-19.